中国伤残医学
中國傷殘醫學
중국상잔의학
CHINESE JOURNAL OF TRAUMA AND DISABILITY MEDICINE
2013年
11期
33-34
,共2页
碘131%抗甲状腺药物%甲状腺功能亢进%疗效
碘131%抗甲狀腺藥物%甲狀腺功能亢進%療效
전131%항갑상선약물%갑상선공능항진%료효
I131%Antithyroid drugs%Hyperthyroidism%Curative effect
目的:探讨碘131和抗甲状腺药物治疗甲状腺功能亢进的疗效。方法:选择2009年5月~2013年5月间于我院就诊的甲状腺功能亢进患者为研究对象,按照治疗方法的不同分为治疗组和对照组,治疗组的患者接受碘131治疗,对照组患者采用抗甲状腺药物治疗。观察治疗1年后2组患者的有效率和复发情况。结果:治疗1年后,治疗组的有效率为92.86%,观察组的有效率为65.85%,差异有统计学意义( P<0.05)。治疗组的复发率为2.38%,观察组的复发率为19.51%,差异有统计学意义( P<0.05)。结论:碘131是一种治疗甲状腺功能亢进的安全可靠、疗效明显的方法,可以在临床上推广使用,但其远期疗效仍需进一步的探讨。
目的:探討碘131和抗甲狀腺藥物治療甲狀腺功能亢進的療效。方法:選擇2009年5月~2013年5月間于我院就診的甲狀腺功能亢進患者為研究對象,按照治療方法的不同分為治療組和對照組,治療組的患者接受碘131治療,對照組患者採用抗甲狀腺藥物治療。觀察治療1年後2組患者的有效率和複髮情況。結果:治療1年後,治療組的有效率為92.86%,觀察組的有效率為65.85%,差異有統計學意義( P<0.05)。治療組的複髮率為2.38%,觀察組的複髮率為19.51%,差異有統計學意義( P<0.05)。結論:碘131是一種治療甲狀腺功能亢進的安全可靠、療效明顯的方法,可以在臨床上推廣使用,但其遠期療效仍需進一步的探討。
목적:탐토전131화항갑상선약물치료갑상선공능항진적료효。방법:선택2009년5월~2013년5월간우아원취진적갑상선공능항진환자위연구대상,안조치료방법적불동분위치료조화대조조,치료조적환자접수전131치료,대조조환자채용항갑상선약물치료。관찰치료1년후2조환자적유효솔화복발정황。결과:치료1년후,치료조적유효솔위92.86%,관찰조적유효솔위65.85%,차이유통계학의의( P<0.05)。치료조적복발솔위2.38%,관찰조적복발솔위19.51%,차이유통계학의의( P<0.05)。결론:전131시일충치료갑상선공능항진적안전가고、료효명현적방법,가이재림상상추엄사용,단기원기료효잉수진일보적탐토。
Objective:To explore the curative effect of I 131 and antithyroid drugs for hyperthyroidism .Methods:The patients of hy-perthyroidism visiting in the endocrinology department of our hospital from May 2009 to May 2012 were taken as the study objects .The patients were grouped into case and control .The case group was treated with I 131 , and the control group were treated with antithyroid drugs.The observation indexes were effective rate and recurrence rate of the patients .Results:The effective rate of case group was 92. 86%, the effective rate of control group was 65.85%, the difference was statistically significant (P<0.05).The recurrence rate of case group was 2.38%, the recurrence rate of control group was 19.51%, the difference was statistically significant (P<0.05).Conclusion:I131 was a safe, reliable and effective treatment for hyperthyroidism , can be generalized and used in clinical practice .